Fisons' tipredane
Executive Summary
Firm is discontinuing development of the potential asthma and rhinitis treatment licensed from Bristol-Myers Squibb. Tipredane demonstrated an "excellent safety profile," but not "the level of efficacy which would be likely to prove therapeutically useful," the U.K. company said.